Compare ASIX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASIX | CTNM |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.1M | 550.7M |
| IPO Year | 2016 | 2024 |
| Metric | ASIX | CTNM |
|---|---|---|
| Price | $20.22 | $15.24 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.00 | $19.00 |
| AVG Volume (30 Days) | 201.9K | ★ 252.5K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | ★ 11.11 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,684,625,000.00 | N/A |
| Revenue This Year | $4.19 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 45.49 | N/A |
| 52 Week Low | $14.10 | $6.19 |
| 52 Week High | $26.73 | $16.91 |
| Indicator | ASIX | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 45.81 | 57.70 |
| Support Level | $19.22 | $13.23 |
| Resistance Level | $20.48 | $15.52 |
| Average True Range (ATR) | 0.77 | 1.16 |
| MACD | -0.05 | 0.11 |
| Stochastic Oscillator | 26.91 | 65.12 |
AdvanSix Inc is a diversified chemistry company playing a critical role in international supply chains, innovating and delivering essential products for customers across a wide variety of end markets and applications that touch people's lives, including building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives, and electronics. The company's key products include Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates. The majority of sales are from Plant Nutrients products. The company operates in the United States and internationally, with the majority of revenue coming from the United States.
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.